Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC YJ1206 | 3053716-98-3 | 96.9% | 894.01 | 250 MG
Supplier: Medchemexpress LLC 250MGHY168555
YJ1206 is an orally active, selective CDK12/CDK13 PROTAC degrader. It increases DNA damage, induces apoptosis, and promotes tumor regression in orthotopic WA74 patient-derived xenograft (PDX) mice models of resistant prostate cancer. It suppresses tumor growth in vivo in conjunction with AKT pathway inhibitors.
- Increases DNA damage and induces apoptosis.
- Promotes tumor regression in models of resistant prostate cancer.
- Suppresses tumor growth when combined with AKT pathway inhibitors.
- Composed of a CDK12/CDK13 degradation agent, a linker, and a VHL E3 ubiquitin ligase.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?